Illumina’s Damon Hostin said clinical sequencing is positioned to enable more preemptive, preventative medicine, but insurance hurdles continue to limit widespread adoption. Hostin, head of market access for Illumina’s clinical solutions, said entry points have already emerged across key clinical applications that can translate sequencing benefits into reimbursable care. The comment underscores a practical adoption constraint: even when clinical value is demonstrated, payers and coverage decisions can slow uptake. How evidence packages are structured—especially around clinical utility, outcomes, and cost-effectiveness—will likely determine whether sequencing moves from boutique testing into broader routine workflows. For the sector, reimbursement remains a gating factor as sequencing platforms expand into new cohorts and more proactive care settings.